Esketamine nasal spray plus oral antidepressant for treatment-resistant depression

Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Esketamine + oral antidepressant with Placebo nasal spray + oral antidepressant (2 arms). Primary endpoint: Change from baseline in Montgomery-Asberg Depression Rating Scale total score at end of double-blind induction phase. Started Jun 2015; status: completed.